WO2022063576A1 - Composition antibactérienne hydratante - Google Patents

Composition antibactérienne hydratante Download PDF

Info

Publication number
WO2022063576A1
WO2022063576A1 PCT/EP2021/074689 EP2021074689W WO2022063576A1 WO 2022063576 A1 WO2022063576 A1 WO 2022063576A1 EP 2021074689 W EP2021074689 W EP 2021074689W WO 2022063576 A1 WO2022063576 A1 WO 2022063576A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibacterial composition
weight
phase
composition
antibacterial
Prior art date
Application number
PCT/EP2021/074689
Other languages
English (en)
Inventor
Prem Chandar
Bivash Ranjan Dasgupta
Gabriella Satchi Olivia FREY
Teanoosh Moaddel
Anat Shiloach
Original Assignee
Unilever Ip Holdings B.V.
Unilever Global Ip Limited
Conopco, Inc., D/B/A Unilever
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Ip Holdings B.V., Unilever Global Ip Limited, Conopco, Inc., D/B/A Unilever filed Critical Unilever Ip Holdings B.V.
Priority to JP2023518848A priority Critical patent/JP2023545935A/ja
Priority to EP21773572.9A priority patent/EP4216715A1/fr
Priority to US18/026,663 priority patent/US20230310304A1/en
Priority to BR112023005487A priority patent/BR112023005487A2/pt
Priority to MX2023003310A priority patent/MX2023003310A/es
Priority to CA3193716A priority patent/CA3193716A1/fr
Priority to CN202180065132.0A priority patent/CN116456828A/zh
Publication of WO2022063576A1 publication Critical patent/WO2022063576A1/fr
Priority to ZA2023/02162A priority patent/ZA202302162B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions
    • A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18

Definitions

  • the moisturizing antibacterial composition includes water, alcohol, a thickening agent, and a moisturizing oil.
  • Consumers are increasingly concerned with microbial and viral contamination. As such, hygiene continues to be one of the most important attributes desired among consumers. Consumers desire products that will provide the required hygienic properties. Consumers throughout the world use different types of antibacterial compositions for disinfecting various surfaces including hard surfaces such as countertops, floors, and furniture; soft and porous surfaces such as clothes, carpets, and upholstery; and personal surfaces such as skin and hair. Many microorganisms like bacteria and viruses are found on such surfaces. It is desirable to keep these surfaces free of germs to minimize the risk of becoming ill.
  • antibacterial products are commercially available. Some are supplied as gels containing at least 60% by weight or more of ethanol. While such products are known to yield good antibacterial benefits after application, certain consumers shun using high ethanol-based products since such products may dry the skin, weaken the epidermis barrier, and expedite the aging process. In the current environment, consumers may be using antibacterial products on their bodies throughout the day thus increasing the likelihood of developing dry skin.
  • An antibacterial composition comprises: water; alcohol; a thickening agent; and a moisturizing oil, wherein at least 50% of droplets of moisturizing oil present in the antibacterial composition have a particle size of 5 micrometers to 10 millimeters.
  • a method of making an antibacterial composition comprises: dispersing a thickening agent in water forming a first phase; combining a moisturizing oil and a humectant forming a second phase; combining the first phase with an alcohol forming a third phase; adding the second phase to the third phase; and adding a neutralizer to the third phase, thereby forming the antibacterial composition.
  • the antibacterial composition is a moisturizing, opaque to transparent/translucent composition containing visible particulates with non-tacky sensory properties.
  • the antibacterial composition can be any form, including, but not limited to, a liquid, gel, cream or lotion.
  • the antibacterial composition provides moisturization to the surface onto which it is applied. For example, when the composition is applied to human skin, the antibacterial composition does not leave the user with dry skin, but rather with skin that has been both moisturized and sanitized.
  • the antibacterial composition includes water, alcohol, a thickening agent, and a moisturizing oil. It was unexpectedly found that the specific moisturizing oil present in the antibacterial composition disclosed herein leaves the user with non-sticky, moisturized skin after application of the composition without requiring the use of a nontacking agent.
  • the antibacterial composition can be substantially free of a non-tacking agent.
  • substantially free of a non-tacking agent means that the composition contains less than 2% by weight of a non-tacking agent, preferably, less than 1 % by weight of a non-tacking agent, more preferably less than 0.5% by weight of a non-tacking agent, even more preferably, less than 0.1 % by weight of a non-tacking agent, still more preferably, 0% by weight of a non-tacking agent.
  • Percent by weight (% by weight) referred to herein throughout refers to the % by weight in the overall composition.
  • the antibacterial composition advantageously provides both moisturizing and sanitizing benefits to the surface onto which it is applied.
  • Sanitizing or antibacterial composition refers to a composition that is capable of killing bacteria or inhibiting the growth of bacteria as often associated with compositions having at least 60% by weight alcohol.
  • the antibacterial compositions can be substantially emulsifier free, opaque to transparent/translucent with visible particulates. Substantially emulsifier free means that the composition contains less than 3% by weight emulsifier, preferably, less than 2% by weight emulsifier, more preferably less than 0.5% by weight emulsifier.
  • the antibacterial composition contains no emulsifier or stated another way, 0% by weight emulsifier. Reducing the level of or eliminating the use of emulsifier can assist creating a more environmentally friendly composition without the use of an additional ingredient.
  • the antibacterial composition comprises water in an amount of 5 to 30% by weight, preferably 6 to 25% by weight, more preferably 7 to 20% by weight.
  • Alcohol can be used as the antibacterial agent in the composition.
  • the antibacterial composition comprises alcohol in an amount of 60 to 80% by weight, preferably 62 to 75% by weight, more preferably 65 to 75% by weight, including all values and ranges subsumed therein.
  • the alcohol can comprise a variety of alcohols including, but not limited to, ethanol, propanol (e.g., n-propanol), isopropyl alcohol, or a combination thereof.
  • the alcohol can comprise chloroxylenol.
  • a preferred alcohol can be denatured SD-40 ethanol.
  • the antibacterial composition can optionally comprise one or more additional antibacterial agents.
  • the optional, additional antibacterial agent can be selected from terpenes, essential oils, or cationic oils having a solubility in water of less than 2000 parts per million (ppm) at 25°C.
  • aromatic essential oils examples include amyl salicylate, carvacrol, cymene, e.g., p-cymene, dihydroeugenol, eugenol, hexyl eugenol, hexyl salicylate, isoeugenol, methyl eugenol, methyl isoeugenol, methyl salicylate, tert butyl cresol, thymol, and vanillin.
  • non-aromatic essential oils of terpenoid compounds include cedrane, cineole, citral (including geranial and neral), citronellal, nitronelol, eucalyptol (i.e., 1 ,8 cineole) paradihydrolinalool, dihydromyrcenol (DH myrcenol), farnesol, geraniol, hexyl cinnamaldehyde, hydroxycitronallol, hydroxycitronellal, isocitral, limonene, preferably d-limonene, linallol, longifolene, menthol, nerol, nerolidiol, pinene, e.g., a- pinene, phellendrene, terpinine, e.g., a-terpinene and y-terpinene, terpineol, e.g.,
  • Preferred cationic oils include quaternary ammonium cationic vegetable oil and charged aminopolydimethylsilane having the formula (CH3)3-Si[Si(CH3)2-O]-[Si(CH3)-((CH 2 )3-NH- (CH 2 )2-N 2 )-O] 2 -Si-(CH3)3. It is preferred that the solubility of these additional antibacterial agents be less than 2000 ppm at 25°C.
  • the additional antibacterial agent can be terpineol, thymol, eugenol, borneol, limonene, or a combination thereof.
  • a preferred additional antibacterial agent can be terpineol, thymol, or eugenol, or a combination thereof.
  • the silver compound can comprise a silver ion, for example, the silver ion can be selected from silver nitrate, silver acetate, silver oxide, silver sulfate, or a combination thereof.
  • the silver compound is silver nitrate.
  • the silver compounds optionally employed in the compositions are one or more water-soluble silver (I) compounds having a silver ion solubility of at least 1.0X 10 -4 mol/L (in water at 25°C).
  • Silver ion solubility as referred to herein, is a value derived from a solubility product (Ksp) in water at 25°C, a well-known parameter that is reported in numerous sources. More particularly, silver ion solubility [Ag+], a value given in mol/L may be calculated using the formula:
  • [Ag+] (Ksp'X) (1/(x+1)) , wherein Ksp is the solubility product of the compound of interest in water at 25°C, and x represents the number of moles of silver ion per mole of compound. It has been found that silver (I) compounds having a silver ion solubility of at least 1 *1 O' 4 mol/L are desirable for use herein.
  • silver compounds desirable for use herein are silver oxide, silver nitrate, silver acetate, silver sulfate, silver benzoate, silver salicylate, silver carbonate, silver citrate and silver phosphate, or a combination thereof, preferably wherein the silver compound is silver nitrate, silver acetate, silver oxide, silver sulfate, or a combination thereof.
  • the additional antibacterial agent can be included in an amount of 0.05 to 2% by weight, for example, 0.1 to 2% by weight of the overall antibacterial composition including all values and ranges subsumed therein.
  • a moisturizing oil can be used in the antibacterial composition to impart moisture to the surface to which it is applied.
  • the moisturizing oil when applied to human skin, can leave the skin feeling moisturized after application of the antibacterial composition and can assist in preventing excess drying of the skin typically associated with antibacterial compositions due to the antibacterial agent used in the composition.
  • the antibacterial composition comprises a moisturizing oil in an amount of 1 to 15% by weight, preferably 1 to 10% by weight, more preferably, 2 to 7% by weight including all values and ranges subsumed therein.
  • the moisturizing oil can comprise an insoluble moisturizing oil.
  • the moisturizing oil can have a minimum viscosity of 10 kiloPoise (kP) (10 Pascal*seconds (Pa*s)) at 32°C.
  • the moisturizing oil can have a viscosity of 10 to 100 kP (10 to 100 Pa*s) at 32°C, more preferably, the upper limit of viscosity is 25 kP to 200 kP (25 to 200 Pa*s) at 32°C.
  • the moisturizing oil can have a melting point of 35 to 90°C (determined according to ASTMD 127-08).
  • droplets of the moisturizing oil present in the antibacterial composition can have a particle size of 5 micrometers (pm) to 10 millimeters (mm), wherein a majority (i.e. , greater than 50%) of the droplets of the moisturizing oil present in the antibacterial composition have a particle size of 5 pm to 10 mm.
  • a majority of (i.e., at least 50%) of the droplets in the moisturizing oil present in the antibacterial composition are visible to naked eye.
  • the particle size can be 10 pm to 5 mm, for example, 50 pm to 2.5 mm, for example, 100 pm to 1 mm, including any and all ranges subsumed therein.
  • At least 50% of the oil droplets can have a particle size of 5 pm to 10 mm, for example, at least 60% of the oil droplets can have a particle size of 5 pm to 10 mm, for example, at least 70% of the oil droplets can have a particle size of 5 pm to 10 mm, for example, at least 80% of the oil droplets can have a particle size of 5 pm to 10 mm, for example, at least 90% of the oil droplets can have a particle size of 5 pm to 10 mm, for example, all of the oil droplets can have a particle size of 5 pm to 10 mm.
  • the moisturizing oil can optionally contain dyes or pigments allowing the user to see the moisturizing oil clearly within the antibacterial composition.
  • Particle size as referred to herein can be measured using either visual or microscopic observation using an optical microscope fitted with cross-polarizers. Assessment of particle size can be accomplished by placing a sample between two glass plates and observing the sample through the microscope to assess particle size. Alternatively, a Mastersizer 3000 from Malvern Panalytical can be used. The Mastersizer uses laser diffraction to measure the particle sizes of a sample dispersed in water and then uses this information to generate a particle size distribution graph. Particle size is generally reported as D[4,3] which is the volume mean diameter.
  • the sample is dropped into the Mastersizer well with a pipet, the propeller at the bottom of the well is set to 2800 revolutions per minute (RPM), and the sample is allowed to thoroughly disperse (until a preview screen shows consistent peaks). After thoroughly dispersed, ten readings are taken of the particle distributions, and an average result is automatically calculated by the Mastersizer. Generally, this process is performed at least twice to ensure the sample was thoroughly dispersed.
  • RPM revolutions per minute
  • the moisturizing oil can comprise petroleum jelly, natural based non-petroleum jelly, natural fats and oil, or a combination thereof.
  • Natural based non-petroleum jelly for example could be plant or bio-derived.
  • Other possible, optional moisturizing oils present at total levels of less than about 2, 1 .0, or 0.5% by wt. in the antimicrobial composition include but are not limited to the following:
  • silicone oils and modifications thereof such as linear and cyclic polydimethylsiloxanes; amino, alkyl, alkylaryl, and aryl silicone oils;
  • silicone elastomers such as dimethicone cross-polymers and hydrophobically modified dimethicone cross polymers
  • fats and oils including natural fats and oils such as jojoba, soybean, sunflower, rice bran, avocado, almond, olive, sesame, persic, castor, coconut, mink oils; cacao fat; beef tallow, lard; hardened oils obtained by hydrogenating the aforementioned oils; and synthetic mono, di and triglycerides such as myristic acid glyceride and 2-ethylhexanoic acid glyceride;
  • waxes such as carnauba, spermaceti, beeswax, lanolin, candelilla, microcrystalline and derivatives thereof;
  • hydrocarbons such as polybutene, liquid paraffins, ceresin, squalene, squalane, pristane and mineral oil;
  • higher fatty acids such as lauric, myristic, palmitic, stearic, behenic, oleic, linoleic, linolenic, lanolic, isostearic, arachidonic and poly unsaturated fatty acids (PUFA);
  • PUFA poly unsaturated fatty acids
  • esters such as cetyl octanoate, cetyl lactate, isopropyl myristate, myristyl myristate, isopropyl palmitate, isopropyl adipate, butyl stearate, decyl oleate, cholesterol isostearate, glycerol monostearate, glycerol distearate, glycerol tristearate, alkyl lactate, alkyl citrate and alkyl tartrate;
  • esters such as cetyl octanoate, cetyl lactate, isopropyl myristate, myristyl myristate, isopropyl palmitate, isopropyl adipate, butyl stearate, decyl oleate, cholesterol isostearate, glycerol monostearate, glycerol distearate, glycerol tristearate, alkyl lactate, alkyl citrate and
  • essential oils and extracts thereof such as mentha, jasmine, camphor, white cedar, bitter orange peel, ryu, turpentine, cinnamon, bergamot, citrus unshiu, calamus, pine, lavender, bay, clove, hiba, eucalyptus, lemon, starflower, thyme, peppermint, rose, sage, sesame, ginger, basil, juniper, lemon grass, rosemary, rosewood, avocado, grape, grapeseed, myrrh, cucumber, watercress, calendula, elder flower, geranium, linden blossom, amaranth, seaweed, ginko, ginseng, carrot, guarana, tea tree, jojoba, comfrey, oatmeal, cocoa, neroli, vanilla, green tea, penny royal, aloe vera, menthol, cineole, eugenol, citral, Citronelle, borneol, linalool, geraniol,
  • the composition is substantially free of silicone.
  • substantially free of silicone means that the composition contains less than 2% by weight of silicone, preferably, less than 1% by weight silicone, more preferably less than 0.5% by weight silicone, even more preferably, less than 0.1 % by weight silicone, still more preferably, 0% by weight silicone.
  • the antibacterial composition can additionally contain other ingredients in addition to those previously described herein including, but not limited to, skin benefit agents, fragrances, preservatives, surfactants, fixatives, opacifiers, chelators, thickening agents, humectants, thickening agents, or a combination thereof.
  • humectants can optionally be used in the antibacterial composition to provide additional moisturization properties to the composition.
  • humectants desirable for use in the antibacterial composition can include water soluble polyols such as propylene glycol, dipropylene glycol, polypropylene glycol (e.g., PPG-9), polyethylene glycol, hydroxypropyl sorbitol, hexylene glycol, 1 ,3-butylene glycol, 1 ,2-octane diol, 1 ,2- hexane diol, isoprene glycol, 1 ,2,6-hexanetriol, ethoxylated glycerol, propoxylated glycerol and combinations thereof.
  • water soluble polyols such as propylene glycol, dipropylene glycol, polypropylene glycol (e.g., PPG-9), polyethylene glycol, hydroxypropyl sorbitol, hexylene glycol, 1
  • glycerin butylene glycol, propylene glycol, polyethylene glycols, sorbitol, polyglycerol, isoprene glycol, or a combination thereof.
  • the humectant can be present in an amount of 1 to 10% by weight, preferably 2 to 8% by weight, more preferably 3 to 7% by weight of the antibacterial composition.
  • compositions to optionally include thickening agents.
  • Thickening agents can be used in the antibacterial composition to assist in forming the composition (e.g., giving it structure). Thickening agents can be used in an amount of 0.01% by weight to 2.5% by weight, for example, 0.1 % by weight to 2.0% by weight, for example, 0.15% by weight to 1.5% by weight, for example, 0.2% by weight to 1.0% by weight including all values and ranges subsumed therein.
  • the amount of thickening agent to be used can be adjusted based on the desired end use viscosity.
  • typical end use polymer concentrations can range from 0.1 -0.5% by weight resulting in viscosities ranging from 1 to 25,000 mPa*s, depending on the choice of the particular Carbopol® polymer being used.
  • Thickening agents can comprise anionic thickening agents, nonionic thickening agents, cationic thickening agents, or a combination thereof.
  • the thickening agent can comprise a hydrophobically modified crosspolymer. Synthetic polymers are effective thickening agents.
  • Possible thickening agents include crosslinked polyacrylates such as the carbomers like ASHLANDTM 980 carbomers (cross linked polymer of acrylic acid), acrylate copolymers, acrylates/ acrylate (C10-C30) alkyl acrylate crosspolymers such as the Carbopol® line like Ultrez20 and ETD2020 commercially available from Lubrizol with an INCI name of acrylates/C 10-30 alkyl acrylate crosspolymer, still further Carbopo® series of polymers can also include UltrezIO, Ultrez21 and Aqua SF-1.
  • crosslinked polyacrylates such as the carbomers like ASHLANDTM 980 carbomers (cross linked polymer of acrylic acid), acrylate copolymers, acrylates/ acrylate (C10-C30) alkyl acrylate crosspolymers such as the Carbopol® line like Ultrez20 and ETD2020 commercially available from Lubrizol with an INCI name of acrylates/C 10-30 alkyl acryl
  • thickening agents desirable for use can include polyacrylamides such as Sepigel® 305 and taurate copolymers such as Simulgel® EG and Aristoflex® AVC, the copolymers being identified by respective INCI nomenclature as sodium acrylate/sodium acryloyldimethyl taurate and acryloyl dimethyltaurate/vinyl pyrrolidone copolymer.
  • Still other thickening polymers can include a synthetic polymer such as an acrylate-based polymer made commercially available by Seppic and sold under the name Simulgel INS100. Calcium carbonate, fumed silica, and magnesium-aluminum-silicate may also be used.
  • Still further thickening agents classified as polysaccharides can be used.
  • examples include fibers, starches, natural/synthetic gums and cellulosics.
  • Representative of the starches are chemically modified starches such as sodium hydroxypropyl starch phosphate and aluminum starch octenylsuccinate.
  • Tapioca starch is often preferred, as is maltodextrin.
  • Gums include xanthan, tara, sclerotium, pectin, karaya, arabic, agar, guar (including Acacia Senegal guar), carrageenan, alginate and combinations thereof.
  • Cellulosics include hydroxypropyl cellulose, hydroxypropyl methylcellulose (e.g., BENECELTM E10M by Ashland), ethylcellulose, sodium carboxy methylcellulose (cellulose gum/carboxymethyl cellulose) and cellulose (e.g. cellulose microfibrils, cellulose nanocrystals or microcrystalline cellulose).
  • Sources of cellulose microfibrils include secondary cell wall materials (e.g. wood pulp, cotton), bacterial cellulose, and primary cell wall materials.
  • the source of primary cell wall material is selected from parenchymal tissue from fruits, roots, bulbs, tubers, seeds, leaves and combination thereof; more preferably is selected from citrus fruit, tomato fruit, peach fruit, pumpkin fruit, kiwi fruit, apple fruit, mango fruit, sugar beet, beet root, turnip, parsnip, maize, oat, wheat, peas and combinations thereof; and even more preferably is selected from citrus fruit, tomato fruit and combinations thereof.
  • a most preferred source of primary cell wall material is parenchymal tissue from citrus fruit.
  • Citrus fibers, such as those made available by Herbacel® as AQ Plus can also be used as source for cellulose microfibrils.
  • the cellulose sources can be surface modified by any of the known methods including those described in Colloidal Polymer Science, Kalia et al., “Nanofibrillated cellulose: surface modification and potential applications” (2014), Vol 292, Pages 5-31.
  • thickening agents often desired can also include maltodextrin, xanthan gum, and carboxymethyl cellulose, dilinoleyl/dimethyl carbonate copolymer, stearyl alkonium hectorite, tara gum, polyquaternium 32 and/or 37, pentaerythrityl tetrastearate or a combination thereof.
  • the antibacterial composition can optionally contain surfactants, for example, cationic surfactants.
  • the cationic surfactant is only limited in that it should be able to be used for topical application onto human skin.
  • the cationic surfactant can comprise branched or straight chain alkyl trimonium compounds, alkanol trimonium compounds or a combination thereof.
  • the alkanol trimonium compounds include lauroyl ethyltrimonium methosulfate, palmitoyl ethyltrimonium methosulfate, stearoyl ethyltrimonium methosulfate, carnitine, palmitoyl carnitine, a combination thereof or the like.
  • the trimonium compound used can be an alkyl trimonium compound comprising cetrimonium chloride, cetrimonium bromide, mytrimonium chloride, mytrimonium bromide, behentrimonium methosulfate, cocotrimonium methosulfate, behentrimonium chloride, behentrimonium bromide, steartrimonium chloride, steartrimonium bromide, laurtrimonium chloride, laurtrimonium bromide, a combination thereof or the like.
  • cationic surfactant used in the antibacterial composition disclosed herein can consist essentially of or consist of any combination of the aforementioned surfactants.
  • the cationic surfactant comprising a dimonium compound such a compound includes dialkyl dimonium compounds like distearyl dimonium chloride, didecyl dimonium chloride, dicoco dimonium chloride, a combination thereof or the like.
  • dimonium compounds suitable for use include benzethonium chloride and/or benzalkonium chloride.
  • the dimonium and trimonium compounds used herein are meant to include salts of the same, especially chlorides and bromides of the same.
  • Polyquaternium materials can also be used and can include materials such as polyquaternium-6, polyquaternium-10, polyquaternium-16, polyquaternium-45, polyquaternium-28, polyquaternium-53, polyquaternium-67, acrylamidepropyl-trimonium chloride/acrylate (or acrylamide) copolymer, a combination thereof or the like.
  • the amount of cationic surfactant (i.e., cationic trimonium, dimonium) and/or polyquaternium material when used in the composition is typically 0.007 to 5% by weight, and preferably, from 0.01 to 3% by weight, and most preferably, from 0.05 to 1% by weight, based on total weight of the composition, including all values and ranges subsumed therein.
  • trimonium and dimonium surfactant are often used in a weight ratio of 1 :99 to 99: 1 , and preferably, from 30:70 to 70:30, and most preferably, from 40:60 to 60:40.
  • the antibacterial composition can also optionally include sunscreens and photostabilizers.
  • the sunscreens and photostabilizers for use include such materials as octylmethoxycinnamate (OMC), ethylhexyl salicylate, phenylbenzimidazole sulfonic acid (Ensulizole), ethylhexyl p-methoxycinnamate, available as Parsol MCX®, Avobenzene (butyl methoxydibenzoylmethane), available as Parsol 1789® and benzophenone-3, also known as oxybenzone.
  • OMC octylmethoxycinnamate
  • Ensulizole phenylbenzimidazole sulfonic acid
  • Parsol 1789® Parsol 1789®
  • benzophenone-3 also known as oxybenzone.
  • Still others can inlcude bis-ethyl hexyloxyphenol methoxyphenol triazine, 2-ethylhexyl-2-cyano3,3-diphenyl-2-propanoic acid, drometrizole trisiloxane, 3,3,5-trimethyl cyclohexyl 2-hydroxybenzoate, 2-ethylhexyl-2- hydroxybenzoate or combination thereof.
  • Inorganic sunscreen actives may be employed such as microfine titanium dioxide (preferably with a particle diameter of less than 150 nanometers (nm), and most preferably, less than 100 nm) and zinc oxide may be used, polyethylene and various other polymers are also suitable sunscreens.
  • sunscreens suitable for use include p-aminobenzoic acid (PABA), octyldimethyl-PABA, 2-ethoxyethyl p-methoxy cinnamate, benzophenone-1 , benzophenone-2, benzophenone-6, benzophenone-8, benzophenone-9, benzophenone-12, homomethyl salicylate, menthyl anthranilate, benzophenone-4, triethanolamine salicylate, terephthalylidene dicamphor sulfonic acid, bisoctriazole, bisethylhexyloxyphenol methoxyphenyl triazine, bisdisulizole disodium, diometriazole trisiloxane, octyltriazone, iscotrizinol, polysilicone-15, isopentenyl-4-methoxycinnamate, or a combination thereof.
  • PABA p-aminobenzoic acid
  • Octocrylene can also be used.
  • Amounts of the sunscreen or photostabilizing agents when present can be 0.001 to 20%, preferably, 0.005 to 15%, optimally, 0.01 to 10%, or even 0.1 to 0.2% by weight of the antibacterial composition including all values and ranges subsumed therein.
  • water-soluble skin benefit agents suitable to use in the antibacterial composition disclosed herein include acids, such as amino acids like arginine, valine or histidine.
  • Vitamins can be used such as vitamin B2, picolinamide, niacinamide (vitamin B3), panthenol (vitamin B5), vitamin Be, vitamin C, a combination thereof or the like.
  • Derivatives, and especially, water soluble derivatives of such vitamins can also be employed.
  • vitamin C derivatives such as ascorbyl tetraisopalmitate, magnesium ascorbyl phosphate and ascorbyl glycoside may be used alone or in combination with each other.
  • skin benefit agents that can be used include hyaluronic acid and salts thereof (like Na+ and K+ salts of the same) 4-ethyl resorcinol, extracts like sage, aloe vera, green tea, sugar cane, citrus, grapeseed, thyme, chamomile, yarrow, cucumber, liquorice, rosemary extract or a combination thereof.
  • Water soluble sunscreens like ensulizole may also be used as may electrolytes such as NaCI and/or KOI.
  • the total amount of optional water-soluble benefit agents (including mixtures) when present in the composition disclosed herein can be 0.0001 to 10%, preferably, 0.001 to 6.5%, and most preferably, 0.01 to 3.5% by weight, based on total weight of the antibacterial composition and including all values and ranges subsumed therein.
  • oil soluble benefit agents include components like stearic acid, vitamins like vitamin A, D, E and K (and their oil soluble derivatives).
  • the composition can comprise Vitamin A in an amount of 0.001 to 0.75% by weight, preferably 0.01 to 0.5% by weight of the antibacterial composition, including all values and ranges subsumed therein.
  • oil soluble benefit agents for use include resorcinols like 4-hexyl resorcinol, 4-butyl resorcinol, 4-phenylethyl resorcinol, 4-cyclopentyl resorcinol, 4- cyclohexyl resorcinol 4-isopropyl resorcinol or a combination thereof.
  • resorcinols like 4-hexyl resorcinol, 4-butyl resorcinol, 4-phenylethyl resorcinol, 4-cyclopentyl resorcinol, 4- cyclohexyl resorcinol 4-isopropyl resorcinol or a combination thereof.
  • 5-substituted resorcinols like 4-cyclohexyl-5-methylbenzene-1 ,3-diol, 4-isopropyl-5-methylbenzene- 1 ,3-diol, combination thereof
  • oil soluble benefit agents that can be used include omega-3 fatty acids, omega-6 fatty acids, climbazole, magnolol, honokiol, farnesol, ursolic acid, myristic acid, geranyl geraniol, oleyl betaine, cocoyl hydroxyethyl imidazoline, hexanoyl sphingosine, 12-hydroxystearic acid, petroselinic acid, conjugated linoleic acid, stearic acid, palmitic acid, lauric acid, terpineol, thymol essential components, the dissolution auxiliary selected from limonene, pinene, camphene, cymene, citronellol, citronellal, geraniol, nerol, linalool, rhodinol, borneol, isoborneol, menthone, camphor, safrole, isosafrole, eugeno
  • retinoic acid precursor can be retinol, retinal, retinyl propionate, retinyl palmitate, retinyl acetate or a combination thereof. Retinyl propionate, retinyl palmitate and combinations thereof are typically preferred. Still another retinoic acid precursor for use is hydroxyanasatil retinoate made commercially available under the name Retextra® as supplied by Molecular Design International. The same may be used in a combination with any of the oil soluble benefit agents described herein.
  • oil soluble benefit agent When an optional (i.e., 0.0 to 1.5% by weight) oil soluble benefit agent is used in the antibacterial composition, it typically is present in an amount of 0.001 to 1.3%, and for example, 0.05 to 1.2%, for example, 0.1 to 0.5% by weight of the total weight of the end use composition, including all values and ranges subsumed therein.
  • Film forming agents may be used in the antibacterial compositions. While optional, such agents can aid with the composition adhering to the surface to which it is applied. Film forming agents include those having hydrophilic properties and they include materials comprising polyvinylpyrrolidone (PVP), acrylates, acrylamides, and copolymers thereof. Deposition agents like organosiloxanes and polyquaternium-7 (MerquatTM S Polymer from Lubrizol) may also be used. When used, such agents make up from 0.001 to 1% by weight of the antibacterial composition including all values and ranges subsumed therein.
  • anti-mosquito agents like eucalyptus oil, lavender oil, N,N-diethyl-meta-toluamide (DEET), a combination thereof or the like.
  • DEET N,N-diethyl-meta-toluamide
  • other ingredients which may be used include octopirox (piroctone), zinc pyrithione, chloroxylenol, triclosan, cetylpyridinium chloride as well as silver compounds including silver oxide, nitrate, sulfate, phosphate, carbonate, acetate, benzoate, a combination thereof or the like. If used, these other components typically make up from 0.001 to 1.6%, and preferably, from 0.01 to 1.2% by weight of the antibacterial composition including all values and ranges subsumed therein.
  • Preservatives can optionally be used in the antibacterial composition disclosed herein.
  • illustrative preservatives include sodium benzoate, iodopropynyl butyl carbamate, phenoxyethanol, hydroxyacetophenone, ethylhexylglycerine, methyl paraben, propyl paraben, imidazolidinyl urea, sodium dehydroacetate, dimethyl-dimethyl (DM DM) hydantoin and benzyl alcohol or a combination thereof.
  • Other preservatives suitable for use include sodium dehydroacetate, chlorophenesin and decylene glycol.
  • Preservatives are preferably employed in amounts of 0.01 % to 2.0% by weight of the total weight of antibacterial composition, including all values and ranges subsumed therein. Also preferred is a preservative system with hydroxyacetophenone alone or in a mixture with other preservatives.
  • Fragrances, fixatives, opacifiers (like titanium dioxide), chelators (like EDTA) may optionally be included in the antibacterial composition.
  • Each of these substances may be present in an amount of about 0.03 to about 3%, preferably, about 0.1 to about 2.6% by weight of the total weight of the antibacterial composition, including all values and ranges subsumed therein.
  • hemp oil with 2.5 to 25% by weight cannabigerol and/or cannabidiol at from 0.5 to 10 percent by weight.
  • hemp oil makes up 0.0001 to 1.5% by weight of the antibacterial composition, and preferably, 0.01 to 1 % by weight of the antibacterial composition, if used, including all values and ranges subsumed therein.
  • the antibacterial composition can optionally contain an emulsifier.
  • the emulsifier may be selected from the group consisting of those with a C10-C20 fatty alcohol or acid hydrophobe condensed with about 2 to about 100 moles of ethylene oxide or propylene oxide per mole of hydrophobe; C2-C10 alkyl phenols condensed with 2 to 20 moles of alkylene oxide; mono- and di-fatty acid esters of ethylene glycol; sorbitan, mono- and di- C8-C20 fatty acids; and polyoxyethylene sorbitan, or a combinations thereof.
  • Alkyl polyglycosides and saccharide fatty amides e.g. methyl gluconamides
  • nonionic emulsifiers e.g. methyl gluconamides
  • nonionic emulsifier can include polysorbate 20 (Tween 20), polyoxyethylene (20) sorbitan monooleate (Tween 80).
  • Other emulsifiers that can be used include emulsifying wax, cetearyl glucoside and combinations with cetearyl alcohol also known as Montanov 68, or a combination thereof.
  • the emulsifier can be present in an amount of 0 to 1% by weight, for example, 1% by weight including all values and ranges subsumed therein.
  • the antibacterial compositions can be substantially emulsifier free and opaque to transparent/translucent.
  • Substantially emulsifier free means that the composition contains less than 3% by weight emulsifier, preferably, less than 2% by weight emulsifier, more preferably less than 0.5% by weight emulsifier, most preferably, 0% by weight emulsifier including all values and ranges subsumed therein.
  • the emulsifier can comprise a phospholipid such as hydrogenated phosphatidylcholine (i.e.
  • the antibacterial composition can be substantially free of hydrogenated phosphatidylcholine wherein substantially free refers to an amount of less than 0.05% by weight lecithin being present in the composition. In another embodiment, the antibacterial composition contains no lecithin (i.e., 0% by weight lecithin).
  • the antibacterial composition can additionally contain a neutralizing agent such as sodium hydroxide, potassium hydroxide, triethanolamine, ammonium, arginine, tromethamine, aminomethyl propanol sold as AMP 95, AMP-Ultra PC1000, AMP-Ultra PC2000, AMP-Ultra PC3000 by Angus, tetrahydroxylpropyl ethylenediamine also known as Neutrol TE from BASF, diisopropanolamine, triisopropanolamine, or a combination thereof.
  • the neutralizing agent can be present in an amount of 0 to 1 % by weight, for example, 0.1 to 0.75% by weight, for example, 0.2 to 0.5% by weight including all values and ranges subsumed therein.
  • the level of neutralization of a particular Carbopo® series of polymer can affect the final viscosity of the end use composition. If an anionic thickening agent is used, the level of neutralizer should be added and adjusted (increased/decreased) according to the amount of anionic thickener used to give a consumer acceptable end use viscosity at a skin friendly pH of between 3.5-8.2, more preferably 5-7.5.
  • Particulates, opacifiers and abrasives may also be included in compositions disclosed herein. Each of these substances can be present in an amount of about 0.05 to about 5%, preferably about 0.1 to about 3% by weight of the composition including all values and ranges subsumed therein.
  • packaging the antibacterial composition, can be packaged in a spray bottle, squeeze bottle, or provided as an impregnating wetting agent on cotton swab, wipe, towelette, cosmetic substrate sheet (like those described in US 6,294,182 B1) or the like. As the viscosity is increased with thickening agent, the antibacterial composition gels and may be provided to consumers in a squeeze bottle as a gel composition.
  • the spray bottle may also be metal, and the antibacterial composition may be provided via conventional aerosol packaging technologies and including those which utilize air-in-bag discharging cannisters, mechanisms and actuators. It is also within the scope of the antibacterial composition to include foaming agents (e.g., zwitterionic and/or amphoteric surfactants) so that the antibacterial composition can be discharged as a foam.
  • foaming agents e.g., zwitterionic and/or amphoteric surfactants
  • the antibacterial composition should be supplied with instructions to apply (e.g., squeeze or spray) the composition on to a surface, like skin, for bacteria kill and viral activity reduction.
  • the antibacterial composition can be packaged in biodegradable packaging and the packaging used can be refillable or reusable, biodegradable, and/or at least 50%, and preferably, at least 100% made from post-consumer recycled resin.
  • Skin is meant to include skin on the arms (including underarms), face, feet, neck, chest, hands, legs, buttocks and scalp (including hair).
  • Sanitizing as used herein means a bacteria log kill of at least 2 and a viral log inactivation of at least 2 (both achieved), preferably a bacteria log kill of at least 3 and a viral log inactivation of at least in less than 3 minutes after topical application to a surface.
  • Combination as used herein means, total weight, e.g., of cetrimonium chloride plus benzalkonium chloride.
  • Skin benefit agent means an ingredient suitable to improve a skin characteristic.
  • Surface as used herein includes skin or the surface of an inanimate object such as a tabletop, computer monitor, doorknob, toilet seat, shopping cart handle or even a clothing garment. Surface is also meant to include the coat of an animal such as the fur on a dog and cat. As used herein, surface preferably means human skin, and especially, skin on the face and hands.
  • the antibacterial composition can be a home care composition like a laundry spray composition suitable to spray clothing and upholstery requiring sanitizing.
  • the home care composition can also be an antibacterial kitchen or bathroom spray composition.
  • the antibacterial composition is a topical composition to apply to skin for sanitizing by significantly reducing the amount of bacteria and viruses on the skin.
  • the composition may optionally comprise skin benefit ingredients added thereto such as emollients, vitamins and/or derivatives thereof, resorcinols, retinoic acid precursors, colorants, moisturizers or humectants, fragrances, sunscreens, a combination thereof or the like as previously described herein.
  • the skin benefit ingredients may be water or oil soluble.
  • the antibacterial composition therefore, is a hydroalcoholic based composition with a pH of 3.5 to 8.2, and the composition is water/alcohol continuous.
  • the composition is a non-therapeutic and non-medicinal composition which is a water/alcohol continuous liquid having a viscosity under 30,000 centipoises (cps), preferably having a viscosity under 25,000 cps, preferably having a viscosity of 2, DOO- 25, 000 cps, more preferably having a viscosity of 2,000-10,000 cps.
  • cps centipoises
  • the viscosity of the antibacterial composition will be under 30,000 cps. Often the viscosity of the antibacterial composition will be 0 to 25,000 cps, and preferably, 1500 to 25,000 cps, more preferably, 2,000 to 20,000 cps, and still more preferably, 2,000 to 10,000 cps, including all ranges subsumed therein.
  • the antibacterial compositions can be made by any method of making an antibacterial composition.
  • the antibacterial composition is made at room temperature and the components are mixed until uniformity is reached.
  • a method of making the antibacterial composition disclosed herein can include the following: dispersing a thickening agent in water to form a first phase and combining a moisturizing oil and a humectant to form a second phase.
  • the first phase is then combined with an alcohol to form a third phase and the second phase then added to the third phase.
  • the antibacterial composition is then formed by adding a neutralizer to the third phase.
  • a fragrance can then be added and/or optionally an opacifier.
  • EDTA can be used in the antibacterial compositions.
  • EDTA if present, can be included in the second phase.
  • the present antibacterial compositions are generally made in an ordinary or low shear mixing process without the requirements for high shear mixing or high pressure homogenization.
  • the antibacterial compositions disclosed herein are able to be readily manufactured.
  • the compositions are generally formed at atmospheric pressure and at 25°C.
  • Table 1 shows examples of antibacterial compositions as disclosed herein.
  • the samples are made at room temperature, atmospheric pressure, and standard shear by dispersing a thickening agent in water to form phase A.
  • Alcohol forms phase B.
  • any skin benefit agents, humectants, and insoluble moisturizing oils are combined to form phase C.
  • phases A and B are combined and mixed with an overhead pneumatic mixer until a clear mixture is formed at which point Phase C is added.
  • the neutralizer is then added as Phase D and a fragrance added in Phase E thereby forming the antibacterial composition.
  • PJ1 refers to a natural non-petroleum jelly.
  • the natural non-petroleum jelly can be derived from one or more of the following feedstocks: soy, rapeseed, coconut, palm, lard, tallow, cooking oil, having different chain length hydrocarbons.
  • the natural non- petroleum jelly is not limited to the feedstocks listed herein but can include any natural or bio-derived feedstock.
  • PJ2, in Sample 2 is prepared using a mixture of candelilla wax/soybean oil.
  • PJ3 in Sample 3 is a vegetable derived based jelly from Sonneborn sold under the SonneNatural line.
  • PJ4 is a standard petroleum jelly and is used in Sample 4.
  • Sample 5 is prepared with PJ1 and no Tween 20.
  • Sample 6 is prepared with PJ1 and with no Tween 20.
  • Sample 7 is prepared with PJ1 and with no Tween 20.
  • the antibacterial compositions disclosed herein are able to accommodate high levels of petroleum jelly and yet maintain stability for a period of time such as after 3 months at 40°C with no appreciable drop in viscosity over time or visible phase separation in the composition.
  • Antimicrobial benefits mean at least a log kill of 2, preferably at least a log kill of 3, in under 3 minutes whereby antimicrobial assessment is measured via ASTM International standard method E2783-11 (Reapproved 2016) which sets forth the procedure for measuring antimicrobial activity for water miscible compounds using a time kill procedure.
  • Viral (or virus) inactivation is determined by assessing the impact of microbiocides against viruses as set forth in ASTM International standard method 1052-20.
  • the term comprising is meant to encompass the terms consisting essentially of and consisting of.
  • a composition comprising water, cationic surfactant and preservative is meant to include a composition consisting essentially of the same and a composition consisting of the same.
  • any particular upper concentration can be associated with any particular lower concentration or amount as well as any subranges consumed therein.
  • all ranges disclosed herein are inclusive of the endpoints, and the endpoints are independently combinable with each other (e.g., ranges of “up to 25% by weight, or, more specifically, 5% by weight to 20% by weight, in inclusive of the endpoints and all intermediate values of the ranges of 5% by weight to 25% by weight, etc.). “Combination is inclusive of blends, mixtures, alloys, reaction products, and the like.
  • the terms “first”, “second”, and the like herein do not denote any order, quantity, or importance, but rather are used to distinguish one element from another.
  • the terms “a” and “an” and “the” herein do not denote a limitation of quantity and are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.
  • the suffix “(s)” as used herein is intended to include both the singular and the plural of the term it modifies, thereby including one or more of the term (e.g., the film(s) includes one or more films).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Agronomy & Crop Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

L'invention concerne une composition antibactérienne comprenant de l'eau, de l'alcool, un agent épaississant et une huile hydratante, au moins 50 % des gouttelettes de l'huile hydratante présentes dans la composition antibactérienne ayant une taille de particule allant de 5 micromètres à 10 millimètres. Un procédé de fabrication d'une composition antibactérienne comprend la dispersion d'un agent épaississant dans de l'eau pour former une première phase ; la combinaison d'une huile hydratante et d'un humectant pour former une deuxième phase ; la combinaison de la première phase avec un alcool pour former une troisième phase ; l'ajout de la deuxième phase à la troisième phase, formant une quatrième phase ; et l'ajout d'un neutralisant à la quatrième phase, formant ainsi la composition antibactérienne.
PCT/EP2021/074689 2020-09-25 2021-09-08 Composition antibactérienne hydratante WO2022063576A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2023518848A JP2023545935A (ja) 2020-09-25 2021-09-08 保湿抗菌組成物
EP21773572.9A EP4216715A1 (fr) 2020-09-25 2021-09-08 Composition antibactérienne hydratante
US18/026,663 US20230310304A1 (en) 2020-09-25 2021-09-08 Moisturizing antibacterial composition
BR112023005487A BR112023005487A2 (pt) 2020-09-25 2021-09-08 Composição antibacteriana e método de preparação de uma composição antibacteriana
MX2023003310A MX2023003310A (es) 2020-09-25 2021-09-08 Composicion antibacteriana hidratante.
CA3193716A CA3193716A1 (fr) 2020-09-25 2021-09-08 Composition antibacterienne hydratante
CN202180065132.0A CN116456828A (zh) 2020-09-25 2021-09-08 保湿抗菌组合物
ZA2023/02162A ZA202302162B (en) 2020-09-25 2023-02-21 Moisturizing antibacterial composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063083570P 2020-09-25 2020-09-25
US63/083,570 2020-09-25

Publications (1)

Publication Number Publication Date
WO2022063576A1 true WO2022063576A1 (fr) 2022-03-31

Family

ID=77864583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/074689 WO2022063576A1 (fr) 2020-09-25 2021-09-08 Composition antibactérienne hydratante

Country Status (10)

Country Link
US (1) US20230310304A1 (fr)
EP (1) EP4216715A1 (fr)
JP (1) JP2023545935A (fr)
CN (1) CN116456828A (fr)
AR (1) AR123592A1 (fr)
BR (1) BR112023005487A2 (fr)
CA (1) CA3193716A1 (fr)
MX (1) MX2023003310A (fr)
WO (1) WO2022063576A1 (fr)
ZA (1) ZA202302162B (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294182B1 (en) 1999-03-18 2001-09-25 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Towelette product for minimizing facial fine lines and wrinkles
EP1152744A1 (fr) * 1999-02-12 2001-11-14 The Procter & Gamble Company Compositions de nettoyage de la peau
US20160000669A1 (en) 2013-03-08 2016-01-07 Conopco, Inc., D/B/A Unilever Resorcinol compounds for dermatological use
EP3595621A1 (fr) * 2017-03-16 2020-01-22 Unilever N.V. Composition antimicrobienne comprenant de l'huile essentielle et un lipide antimicrobien

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1152744A1 (fr) * 1999-02-12 2001-11-14 The Procter & Gamble Company Compositions de nettoyage de la peau
US6294182B1 (en) 1999-03-18 2001-09-25 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Towelette product for minimizing facial fine lines and wrinkles
US20160000669A1 (en) 2013-03-08 2016-01-07 Conopco, Inc., D/B/A Unilever Resorcinol compounds for dermatological use
US10470986B2 (en) * 2013-03-08 2019-11-12 Conopco, Inc. Resorcinol compounds for dermatological use
EP3595621A1 (fr) * 2017-03-16 2020-01-22 Unilever N.V. Composition antimicrobienne comprenant de l'huile essentielle et un lipide antimicrobien

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KALIA ET AL.: "Nanofibrillated cellulose: surface modification and potential applications", COLLOIDAL POLYMER SCIENCE, vol. 292, 2014, pages 5 - 31, XP035320488, DOI: 10.1007/s00396-013-3112-9

Also Published As

Publication number Publication date
BR112023005487A2 (pt) 2023-04-25
CA3193716A1 (fr) 2022-03-31
MX2023003310A (es) 2023-04-13
US20230310304A1 (en) 2023-10-05
EP4216715A1 (fr) 2023-08-02
JP2023545935A (ja) 2023-11-01
AR123592A1 (es) 2022-12-21
ZA202302162B (en) 2024-06-26
CN116456828A (zh) 2023-07-18

Similar Documents

Publication Publication Date Title
JP5536457B2 (ja) カプセル化されたフレグランスを含むエマルジョン及びパーソナルケア組成物
TWI436784B (zh) 組成物
US20050265936A1 (en) Cleansing foaming sunscreen lotion
WO2008002666A1 (fr) Compositions fonctionnelles contenant des polysaccharides à modification hydrophobe, cationiques, pour des produits de soins personnels, domestiques & de collectivité et de soins des animaux
EP3532020B1 (fr) Composition d'hygiène féminine
US20160081333A1 (en) High Alcohol Content Sanitizer
CN109803532A (zh) 个人洗涤消毒液
MX2007000180A (es) Composiciones para el cuidado personal con hiposensibilidad mejorada.
JP6377052B2 (ja) 植物レシチンを含む毛髪化粧料組成物
US20220096347A1 (en) Active agents for skin and hair care with sensory modifying properties
EP4216909A1 (fr) Composition hydratante antibactérienne
WO2022002882A1 (fr) Composition désinfectante
WO2022063576A1 (fr) Composition antibactérienne hydratante
WO2007042410A1 (fr) Preparation de nettoyage desodorisante
CA3193220A1 (fr) Composition antibacterienne hydratante
CA3171604A1 (fr) Compositions comprenant des conservateurs d'origine naturelle
EP4326066A2 (fr) Composition antimicrobienne
WO2006117516A2 (fr) Compositions topiques
WO2022128801A1 (fr) Composition de coiffage
US11523978B2 (en) Compositions comprising naturally derived preservatives
US11642290B2 (en) Non-spherical microcapsule
CN117222313A (zh) 抗微生物组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21773572

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2023518848

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3193716

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 202180065132.0

Country of ref document: CN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023005487

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112023005487

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230324

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021773572

Country of ref document: EP

Effective date: 20230425